NCT07389876 2026-02-05
G/GEJ
Fudan University
Recruiting
Clinical Trials
11 trialsNCT03890952 2025-07-24
Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma
Rigshospitalet, Denmark
Phase 2 Completed
NCT06777628 2025-01-16
Immunecheck
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Recruiting
NCT06700421 2024-11-22
Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis
Chongqing University Cancer Hospital
Phase 2 Active not recruiting
NCT06475755 2024-06-26
Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC
Tang-Du Hospital
Phase 2 Not yet recruiting
NCT06423144 2024-05-21
PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7
Shanghai Zhongshan Hospital
Not yet recruiting
NCT06063070 2023-10-02
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT04459078 2022-12-02
Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma
Hunan Cancer Hospital
Phase 2 Unknown
NCT04639284 2021-07-26
Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC
Shanghai Zhongshan Hospital
Unknown
NCT04137588 2021-02-24
Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer
Peking University Cancer Hospital & Institute
Unknown
NCT03461185 2018-03-09
Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer
Xinqiao Hospital of Chongqing
Phase 2 Unknown